$MRNA It broke 💥 the red diagonal resistance with a breakaway gap!
Moderna, Merck rise after late-stage trial win for mRNA cancer therapy
Aug 19, 2026
Shares of Merck (MRK) and Moderna (MRNA) spiked in the premarket on Wednesday after the companies said that their jointly developed messenger RNA-based cancer therapy, intismeran autogene, succeeded in a late-stage trial for patients with melanoma, a type of skin cancer.
The Phase 3 INTerpath-001 trial was designed to evaluate intismeran in combination with Merck's (MRK) blockbuster anti-PD-1 therapy Keytruda in more than 1,100 patients with s